Company CVAbout ERIS Lifesciences Ltd 
ERIS Lifesciences Ltd
Mid Cap
Pharmaceuticals & Drugs
Eris Lifesciences Limited was incorporated on January 25, 2007. Subsequently, the name of the company was changed to 'Eris Lifesciences Private Limited' on February 9, 2007. Further, the Company was converted into a Public Limited cCompany and the name was changed to 'Eris Lifesciences Limited' on February 2, 2017. The Company has a manufacturing plant in Guwahati, Assam and is presently engaged in manufacturing and marketing of pharmaceutical products.
Company Coordinates
Company Details
8th Floor Commerce House -IV, Prahladnagar 100 FT Road Ahmedabad Gujarat : 380015
Registrar Details
Link Intime India Pvt Ltd, C-13 Pannalal Silk Compound, L B S Marg, Bhandup , Mumbai
Capital StructureCapital Structure
Present Equity Capital
INR 13.61 Cr
Number of Shares
13.61 Cr
Face Value
INR 1.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
20-Sep-2024
13.61
13.61
24330
1
Issued under ESOP Scheme
14-Aug-2024
13.61
13.61
6454
1
Issued under ESOP Scheme
09-Apr-2024
13.6
13.60
19186
1
Issued under ESOP Scheme
22-Dec-2023
13.6
13.60
5032
1
issued under ESOP
24-Aug-2023
13.6
13.60
17253
1
Issued under ESOP Scheme
07-Jul-2023
13.6
13.60
12703
1
Issued under ESOP Scheme
10-Apr-2023
13.6
13.60
1054
1
Issued under ESOP Scheme
01-Mar-2023
13.6
13.60
1521
1
Issued under ESOP Scheme
19-Sep-2022
13.6
13.60
18037
1
Issued under ESOP Scheme
08-Sep-2022
13.6
13.60
18037
1
Issued under ESOP Scheme
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
18.51
Mutual Funds
Held by 20 Schemes (16.52%)
FIIs
Held by 134 FIIs (8.35%)
Promoter with highest holding
Amit Indubhusan Bakshi (42.85%)
Highest Public shareholder
Lilac Investments Limited (8.79%)
Individual Investors Holdings
9.29%
Board of Directors
Management
Designation
Remuneration
Amit Indubhushan Bakshi
CMD & Executive Director
4.88 cr
Kaushal Kamlesh Shah
WTD & Executive Director
69.92 lacs
Inderjeet Singh Negi
WTD & Executive Director
1.24 cr
Krishnakumar Vaidyanathan
Executive Director / WTD / Chi
4.49 cr
Sujesh Vasudevan
Independent Non Exe. Director
28.17 lacs
Prashant Gupta
Independent Non Exe. Director
39.75 lacs
Rajeev Narotam Dalal
Independent Non Exe. Director
42.0 lacs
Kalpana Unadkat
Independent Non Exe. Director
45.25 lacs
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
Purchase of stock in Trade
79.588
0%
Purchase of stock in Trade
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Other Operating Income
15.41
1.72%
Other Operating Income
Other Operating Income
Stock DNARevenue and Profits:
Net Sales:
727 Cr
(Quarterly Results - Dec 2024)
Net Profit:
84 Cr
Pharmaceuticals & Drugs
INR 18,533 Cr (Mid Cap)
55.00
33
0.55%
0.90
12.57%
6.58
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
